The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InBioMarin Pharmaceutical Inc. has officially completed its acquisition of Amicus Therapeutics in an all-cash transaction valued at approximately $4.8 billion. The deal was executed at a price of $14.50 per share, significantly expanding BioMarin's footprint in the biotechnology sector. By integrating Amicus, BioMarin adds key treatments such as Galafold, Pombiliti, and Opfolda to its commercial portfolio, targeting Fabry and Pompe diseases. This strategic move is expected to provide immediate revenue-generating assets and bolster the company's long-term market position. BioMarin has indicated that it expects to update its fiscal year 2026 financial guidance following the successful closing of the deal. The acquisition underscores the ongoing consolidation trend within the global healthcare and biopharma industries.